{"file_path": "/Users/sz904/Desktop/11711/LTI_Neural_Navigator/data/2024-02-26/chunk_paper_txt/Shinji_Watanabe_Antiviral_Susceptibilities_of_Distinct_Lineages_of_Influenza_C_and_D_Viruses_chunk_5.txt", "num_qa_pairs": 10, "qa_list": [{"question": " What are the grant numbers mentioned in the text?", "answer": " Grant number 21HA2003 and grant number JP18K10036.", "ref_chunk": "Health, Labour and Welfare, Japan, grant number 21HA2003 and by JSPS KAKENHI, grant number JP18K10036. 7 of 10 Viruses 2023, 15, 244 Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Acknowledgments: We thank Susan Watson for scienti\ufb01c editing. Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest. References 1. 2. 3. 4. 5. 6. 7. 8. 9. Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 2017, 93, 449\u2013463. [CrossRef] Tisdale, M. In\ufb02uenza M2 Ion-Channel and Neuraminidase Inhibitors. In Antimicrobial Drug Resistance; Mayers, D.L., Ed.; Humana Press: Totowa, NJ, USA, 2009; Chapter 31; pp. 421\u2013447. Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of in\ufb02uenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633. [CrossRef] Takashita, E. In\ufb02uenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harb. Perspect. Med. 2020, 11, a038687. [CrossRef] Bright, R.A.; Medina, M.-J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of adamantane resistance among in\ufb02uenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005, 366, 1175\u20131181. [CrossRef] Imai, M.; Yamashita, M.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Kiso, M.; Murakami, J.; Yasuhara, A.; Takada, K.; Ito, M.; Nakajima, N.; et al. In\ufb02uenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are \ufb01t and transmit through respiratory droplets. Nat. Microbiol. 2019, 5, 27\u201333. [CrossRef] Takashita, E.; Ichikawa, M.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Human-to-Human Transmission of In\ufb02uenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg. Infect. Dis. 2019, 25, 2108\u20132111. [CrossRef] Takashita, E.; Kawakami, C.; Ogawa, R.; Morita, H.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. In\ufb02uenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Eurosurveillance 2019, 24, 1900170. [CrossRef] Govorkova, E.A.; Takashita, E.; Daniels, R.S.; Fujisaki, S.; Presser, L.D.; Patel, M.C.; Huang, W.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global update on the susceptibilities of human in\ufb02uenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antivir. Res. 2022, 200, 105281. [CrossRef] 10. Matsuzaki, Y.; Sugawara, K.; Furuse, Y.; Shimotai, Y.; Hongo, S.; Oshitani, H.; Mizuta, K.; Nishimura, H. Genetic Lineage and Reassortment of In\ufb02uenza C Viruses Circulating between 1947 and 2014. J. Virol. 2016, 90, 8251\u20138265. [CrossRef] 11. Huang, C.; Yu, J.; Hause, B.M.; Park, J.Y.; Sreenivasan, C.; Uprety, T.; Sheng, Z.; Wang, D.; Li, F. Emergence of new phylogenetic lineage of In\ufb02uenza D virus with broad antigenicity in California, United States. Emerg. Microbes Infect. 2021, 10, 739\u2013742. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 14. Mishin, V.P.; Patel, M.C.; Chesnokov, A.; De La Cruz, J.; Nguyen, H.T.; Lollis, L.; Hodges, E.; Jang, Y.; Barnes, J.; Uyeki, T.; et al. Susceptibility of In\ufb02uenza A, B, C, and D Viruses to Baloxavir. Emerg. Infect. Dis. 2019, 25, 1969\u20131972. [CrossRef] 15. Takada, K.; Kawakami, C.; Fan, S.; Chiba, S.; Zhong, G.; Gu, C.; Shimizu, K.; Takasaki, S.; Sakai-Tagawa, Y.; Lopes, T.J.S.; et al. A humanized MDCK cell line for the ef\ufb01cient isolation and propagation of human in\ufb02uenza viruses. Nat. Microbiol. 2019, 4, 1268\u20131273. [CrossRef] 16. Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of In\ufb02uenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front. Microbiol. 2018, 9, 3026. [CrossRef] 17. Tilmanis, D.; van Baalen, C.; Oh, D.Y.; Rossignol, J.-F.; Hurt, A.C. The susceptibility of circulating human in\ufb02uenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antivir. Res. 2017, 147, 142\u2013148. [CrossRef] 18. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Chiba, S.; Halfmann, P.; Nagai, H.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against COVID-19 Omicron Variant. N. Engl. J. Med. 2022, 386, 995\u2013998. [CrossRef] 8 of 10 Viruses 2023, 15, 244 19. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Halfmann, P.; Watanabe, S.; Maeda, K.; et al. Ef\ufb01cacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022, 386, 1475\u20131477. [CrossRef] 20. Takashita, E.; Yamayoshi, S.; Fukushi, S.; Suzuki, T.; Maeda, K.; Sakai-Tagawa, Y.; Ito, M.; Uraki, R.; Halfmann, P.; Watanabe, S.; et al. Ef\ufb01cacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N. Engl. J. Med. 2022, 387, 1236\u20131238. [CrossRef] 21. Takashita, E.; Yamayoshi, S.; Simon, V.; van Bakel, H.; Sordillo, E.M.; Pekosz, A.; Fukushi, S.; Suzuki, T.; Maeda, K.; Halfmann, P.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022, 387, 468\u2013470. [CrossRef] 22. Takashita, E.; Yamayoshi, S.; Halfmann, P.; Wilson, N.; Ries, H.; Richardson, A.; Bobholz, M.; Vuyk, W.; Maddox, R.; Baker, D.A.; et al."}, {"question": " Is an Institutional Review Board Statement applicable to this study?", "answer": " No, it is not applicable.", "ref_chunk": "Health, Labour and Welfare, Japan, grant number 21HA2003 and by JSPS KAKENHI, grant number JP18K10036. 7 of 10 Viruses 2023, 15, 244 Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Acknowledgments: We thank Susan Watson for scienti\ufb01c editing. Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest. References 1. 2. 3. 4. 5. 6. 7. 8. 9. Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 2017, 93, 449\u2013463. [CrossRef] Tisdale, M. In\ufb02uenza M2 Ion-Channel and Neuraminidase Inhibitors. In Antimicrobial Drug Resistance; Mayers, D.L., Ed.; Humana Press: Totowa, NJ, USA, 2009; Chapter 31; pp. 421\u2013447. Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of in\ufb02uenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633. [CrossRef] Takashita, E. In\ufb02uenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harb. Perspect. Med. 2020, 11, a038687. [CrossRef] Bright, R.A.; Medina, M.-J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of adamantane resistance among in\ufb02uenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005, 366, 1175\u20131181. [CrossRef] Imai, M.; Yamashita, M.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Kiso, M.; Murakami, J.; Yasuhara, A.; Takada, K.; Ito, M.; Nakajima, N.; et al. In\ufb02uenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are \ufb01t and transmit through respiratory droplets. Nat. Microbiol. 2019, 5, 27\u201333. [CrossRef] Takashita, E.; Ichikawa, M.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Human-to-Human Transmission of In\ufb02uenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg. Infect. Dis. 2019, 25, 2108\u20132111. [CrossRef] Takashita, E.; Kawakami, C.; Ogawa, R.; Morita, H.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. In\ufb02uenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Eurosurveillance 2019, 24, 1900170. [CrossRef] Govorkova, E.A.; Takashita, E.; Daniels, R.S.; Fujisaki, S.; Presser, L.D.; Patel, M.C.; Huang, W.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global update on the susceptibilities of human in\ufb02uenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antivir. Res. 2022, 200, 105281. [CrossRef] 10. Matsuzaki, Y.; Sugawara, K.; Furuse, Y.; Shimotai, Y.; Hongo, S.; Oshitani, H.; Mizuta, K.; Nishimura, H. Genetic Lineage and Reassortment of In\ufb02uenza C Viruses Circulating between 1947 and 2014. J. Virol. 2016, 90, 8251\u20138265. [CrossRef] 11. Huang, C.; Yu, J.; Hause, B.M.; Park, J.Y.; Sreenivasan, C.; Uprety, T.; Sheng, Z.; Wang, D.; Li, F. Emergence of new phylogenetic lineage of In\ufb02uenza D virus with broad antigenicity in California, United States. Emerg. Microbes Infect. 2021, 10, 739\u2013742. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 14. Mishin, V.P.; Patel, M.C.; Chesnokov, A.; De La Cruz, J.; Nguyen, H.T.; Lollis, L.; Hodges, E.; Jang, Y.; Barnes, J.; Uyeki, T.; et al. Susceptibility of In\ufb02uenza A, B, C, and D Viruses to Baloxavir. Emerg. Infect. Dis. 2019, 25, 1969\u20131972. [CrossRef] 15. Takada, K.; Kawakami, C.; Fan, S.; Chiba, S.; Zhong, G.; Gu, C.; Shimizu, K.; Takasaki, S.; Sakai-Tagawa, Y.; Lopes, T.J.S.; et al. A humanized MDCK cell line for the ef\ufb01cient isolation and propagation of human in\ufb02uenza viruses. Nat. Microbiol. 2019, 4, 1268\u20131273. [CrossRef] 16. Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of In\ufb02uenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front. Microbiol. 2018, 9, 3026. [CrossRef] 17. Tilmanis, D.; van Baalen, C.; Oh, D.Y.; Rossignol, J.-F.; Hurt, A.C. The susceptibility of circulating human in\ufb02uenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antivir. Res. 2017, 147, 142\u2013148. [CrossRef] 18. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Chiba, S.; Halfmann, P.; Nagai, H.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against COVID-19 Omicron Variant. N. Engl. J. Med. 2022, 386, 995\u2013998. [CrossRef] 8 of 10 Viruses 2023, 15, 244 19. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Halfmann, P.; Watanabe, S.; Maeda, K.; et al. Ef\ufb01cacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022, 386, 1475\u20131477. [CrossRef] 20. Takashita, E.; Yamayoshi, S.; Fukushi, S.; Suzuki, T.; Maeda, K.; Sakai-Tagawa, Y.; Ito, M.; Uraki, R.; Halfmann, P.; Watanabe, S.; et al. Ef\ufb01cacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N. Engl. J. Med. 2022, 387, 1236\u20131238. [CrossRef] 21. Takashita, E.; Yamayoshi, S.; Simon, V.; van Bakel, H.; Sordillo, E.M.; Pekosz, A.; Fukushi, S.; Suzuki, T.; Maeda, K.; Halfmann, P.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022, 387, 468\u2013470. [CrossRef] 22. Takashita, E.; Yamayoshi, S.; Halfmann, P.; Wilson, N.; Ries, H.; Richardson, A.; Bobholz, M.; Vuyk, W.; Maddox, R.; Baker, D.A.; et al."}, {"question": " What is the Data Availability Statement for this study?", "answer": " Not applicable.", "ref_chunk": "Health, Labour and Welfare, Japan, grant number 21HA2003 and by JSPS KAKENHI, grant number JP18K10036. 7 of 10 Viruses 2023, 15, 244 Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Acknowledgments: We thank Susan Watson for scienti\ufb01c editing. Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest. References 1. 2. 3. 4. 5. 6. 7. 8. 9. Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 2017, 93, 449\u2013463. [CrossRef] Tisdale, M. In\ufb02uenza M2 Ion-Channel and Neuraminidase Inhibitors. In Antimicrobial Drug Resistance; Mayers, D.L., Ed.; Humana Press: Totowa, NJ, USA, 2009; Chapter 31; pp. 421\u2013447. Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of in\ufb02uenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633. [CrossRef] Takashita, E. In\ufb02uenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harb. Perspect. Med. 2020, 11, a038687. [CrossRef] Bright, R.A.; Medina, M.-J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of adamantane resistance among in\ufb02uenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005, 366, 1175\u20131181. [CrossRef] Imai, M.; Yamashita, M.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Kiso, M.; Murakami, J.; Yasuhara, A.; Takada, K.; Ito, M.; Nakajima, N.; et al. In\ufb02uenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are \ufb01t and transmit through respiratory droplets. Nat. Microbiol. 2019, 5, 27\u201333. [CrossRef] Takashita, E.; Ichikawa, M.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Human-to-Human Transmission of In\ufb02uenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg. Infect. Dis. 2019, 25, 2108\u20132111. [CrossRef] Takashita, E.; Kawakami, C.; Ogawa, R.; Morita, H.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. In\ufb02uenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Eurosurveillance 2019, 24, 1900170. [CrossRef] Govorkova, E.A.; Takashita, E.; Daniels, R.S.; Fujisaki, S.; Presser, L.D.; Patel, M.C.; Huang, W.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global update on the susceptibilities of human in\ufb02uenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antivir. Res. 2022, 200, 105281. [CrossRef] 10. Matsuzaki, Y.; Sugawara, K.; Furuse, Y.; Shimotai, Y.; Hongo, S.; Oshitani, H.; Mizuta, K.; Nishimura, H. Genetic Lineage and Reassortment of In\ufb02uenza C Viruses Circulating between 1947 and 2014. J. Virol. 2016, 90, 8251\u20138265. [CrossRef] 11. Huang, C.; Yu, J.; Hause, B.M.; Park, J.Y.; Sreenivasan, C.; Uprety, T.; Sheng, Z.; Wang, D.; Li, F. Emergence of new phylogenetic lineage of In\ufb02uenza D virus with broad antigenicity in California, United States. Emerg. Microbes Infect. 2021, 10, 739\u2013742. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 14. Mishin, V.P.; Patel, M.C.; Chesnokov, A.; De La Cruz, J.; Nguyen, H.T.; Lollis, L.; Hodges, E.; Jang, Y.; Barnes, J.; Uyeki, T.; et al. Susceptibility of In\ufb02uenza A, B, C, and D Viruses to Baloxavir. Emerg. Infect. Dis. 2019, 25, 1969\u20131972. [CrossRef] 15. Takada, K.; Kawakami, C.; Fan, S.; Chiba, S.; Zhong, G.; Gu, C.; Shimizu, K.; Takasaki, S.; Sakai-Tagawa, Y.; Lopes, T.J.S.; et al. A humanized MDCK cell line for the ef\ufb01cient isolation and propagation of human in\ufb02uenza viruses. Nat. Microbiol. 2019, 4, 1268\u20131273. [CrossRef] 16. Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of In\ufb02uenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front. Microbiol. 2018, 9, 3026. [CrossRef] 17. Tilmanis, D.; van Baalen, C.; Oh, D.Y.; Rossignol, J.-F.; Hurt, A.C. The susceptibility of circulating human in\ufb02uenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antivir. Res. 2017, 147, 142\u2013148. [CrossRef] 18. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Chiba, S.; Halfmann, P.; Nagai, H.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against COVID-19 Omicron Variant. N. Engl. J. Med. 2022, 386, 995\u2013998. [CrossRef] 8 of 10 Viruses 2023, 15, 244 19. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Halfmann, P.; Watanabe, S.; Maeda, K.; et al. Ef\ufb01cacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022, 386, 1475\u20131477. [CrossRef] 20. Takashita, E.; Yamayoshi, S.; Fukushi, S.; Suzuki, T.; Maeda, K.; Sakai-Tagawa, Y.; Ito, M.; Uraki, R.; Halfmann, P.; Watanabe, S.; et al. Ef\ufb01cacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N. Engl. J. Med. 2022, 387, 1236\u20131238. [CrossRef] 21. Takashita, E.; Yamayoshi, S.; Simon, V.; van Bakel, H.; Sordillo, E.M.; Pekosz, A.; Fukushi, S.; Suzuki, T.; Maeda, K.; Halfmann, P.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022, 387, 468\u2013470. [CrossRef] 22. Takashita, E.; Yamayoshi, S.; Halfmann, P.; Wilson, N.; Ries, H.; Richardson, A.; Bobholz, M.; Vuyk, W.; Maddox, R.; Baker, D.A.; et al."}, {"question": " Who is thanked for scientific editing in the Acknowledgments section?", "answer": " Susan Watson.", "ref_chunk": "Health, Labour and Welfare, Japan, grant number 21HA2003 and by JSPS KAKENHI, grant number JP18K10036. 7 of 10 Viruses 2023, 15, 244 Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Acknowledgments: We thank Susan Watson for scienti\ufb01c editing. Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest. References 1. 2. 3. 4. 5. 6. 7. 8. 9. Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 2017, 93, 449\u2013463. [CrossRef] Tisdale, M. In\ufb02uenza M2 Ion-Channel and Neuraminidase Inhibitors. In Antimicrobial Drug Resistance; Mayers, D.L., Ed.; Humana Press: Totowa, NJ, USA, 2009; Chapter 31; pp. 421\u2013447. Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of in\ufb02uenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633. [CrossRef] Takashita, E. In\ufb02uenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harb. Perspect. Med. 2020, 11, a038687. [CrossRef] Bright, R.A.; Medina, M.-J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of adamantane resistance among in\ufb02uenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005, 366, 1175\u20131181. [CrossRef] Imai, M.; Yamashita, M.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Kiso, M.; Murakami, J.; Yasuhara, A.; Takada, K.; Ito, M.; Nakajima, N.; et al. In\ufb02uenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are \ufb01t and transmit through respiratory droplets. Nat. Microbiol. 2019, 5, 27\u201333. [CrossRef] Takashita, E.; Ichikawa, M.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Human-to-Human Transmission of In\ufb02uenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg. Infect. Dis. 2019, 25, 2108\u20132111. [CrossRef] Takashita, E.; Kawakami, C.; Ogawa, R.; Morita, H.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. In\ufb02uenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Eurosurveillance 2019, 24, 1900170. [CrossRef] Govorkova, E.A.; Takashita, E.; Daniels, R.S.; Fujisaki, S.; Presser, L.D.; Patel, M.C.; Huang, W.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global update on the susceptibilities of human in\ufb02uenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antivir. Res. 2022, 200, 105281. [CrossRef] 10. Matsuzaki, Y.; Sugawara, K.; Furuse, Y.; Shimotai, Y.; Hongo, S.; Oshitani, H.; Mizuta, K.; Nishimura, H. Genetic Lineage and Reassortment of In\ufb02uenza C Viruses Circulating between 1947 and 2014. J. Virol. 2016, 90, 8251\u20138265. [CrossRef] 11. Huang, C.; Yu, J.; Hause, B.M.; Park, J.Y.; Sreenivasan, C.; Uprety, T.; Sheng, Z.; Wang, D.; Li, F. Emergence of new phylogenetic lineage of In\ufb02uenza D virus with broad antigenicity in California, United States. Emerg. Microbes Infect. 2021, 10, 739\u2013742. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 14. Mishin, V.P.; Patel, M.C.; Chesnokov, A.; De La Cruz, J.; Nguyen, H.T.; Lollis, L.; Hodges, E.; Jang, Y.; Barnes, J.; Uyeki, T.; et al. Susceptibility of In\ufb02uenza A, B, C, and D Viruses to Baloxavir. Emerg. Infect. Dis. 2019, 25, 1969\u20131972. [CrossRef] 15. Takada, K.; Kawakami, C.; Fan, S.; Chiba, S.; Zhong, G.; Gu, C.; Shimizu, K.; Takasaki, S.; Sakai-Tagawa, Y.; Lopes, T.J.S.; et al. A humanized MDCK cell line for the ef\ufb01cient isolation and propagation of human in\ufb02uenza viruses. Nat. Microbiol. 2019, 4, 1268\u20131273. [CrossRef] 16. Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of In\ufb02uenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front. Microbiol. 2018, 9, 3026. [CrossRef] 17. Tilmanis, D.; van Baalen, C.; Oh, D.Y.; Rossignol, J.-F.; Hurt, A.C. The susceptibility of circulating human in\ufb02uenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antivir. Res. 2017, 147, 142\u2013148. [CrossRef] 18. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Chiba, S.; Halfmann, P.; Nagai, H.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against COVID-19 Omicron Variant. N. Engl. J. Med. 2022, 386, 995\u2013998. [CrossRef] 8 of 10 Viruses 2023, 15, 244 19. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Halfmann, P.; Watanabe, S.; Maeda, K.; et al. Ef\ufb01cacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022, 386, 1475\u20131477. [CrossRef] 20. Takashita, E.; Yamayoshi, S.; Fukushi, S.; Suzuki, T.; Maeda, K.; Sakai-Tagawa, Y.; Ito, M.; Uraki, R.; Halfmann, P.; Watanabe, S.; et al. Ef\ufb01cacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N. Engl. J. Med. 2022, 387, 1236\u20131238. [CrossRef] 21. Takashita, E.; Yamayoshi, S.; Simon, V.; van Bakel, H.; Sordillo, E.M.; Pekosz, A.; Fukushi, S.; Suzuki, T.; Maeda, K.; Halfmann, P.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022, 387, 468\u2013470. [CrossRef] 22. Takashita, E.; Yamayoshi, S.; Halfmann, P.; Wilson, N.; Ries, H.; Richardson, A.; Bobholz, M.; Vuyk, W.; Maddox, R.; Baker, D.A.; et al."}, {"question": " Do the authors have any conflicts of interest?", "answer": " No, the authors declare no conflict of interest.", "ref_chunk": "Health, Labour and Welfare, Japan, grant number 21HA2003 and by JSPS KAKENHI, grant number JP18K10036. 7 of 10 Viruses 2023, 15, 244 Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Acknowledgments: We thank Susan Watson for scienti\ufb01c editing. Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest. References 1. 2. 3. 4. 5. 6. 7. 8. 9. Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 2017, 93, 449\u2013463. [CrossRef] Tisdale, M. In\ufb02uenza M2 Ion-Channel and Neuraminidase Inhibitors. In Antimicrobial Drug Resistance; Mayers, D.L., Ed.; Humana Press: Totowa, NJ, USA, 2009; Chapter 31; pp. 421\u2013447. Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of in\ufb02uenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633. [CrossRef] Takashita, E. In\ufb02uenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harb. Perspect. Med. 2020, 11, a038687. [CrossRef] Bright, R.A.; Medina, M.-J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of adamantane resistance among in\ufb02uenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005, 366, 1175\u20131181. [CrossRef] Imai, M.; Yamashita, M.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Kiso, M.; Murakami, J.; Yasuhara, A.; Takada, K.; Ito, M.; Nakajima, N.; et al. In\ufb02uenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are \ufb01t and transmit through respiratory droplets. Nat. Microbiol. 2019, 5, 27\u201333. [CrossRef] Takashita, E.; Ichikawa, M.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Human-to-Human Transmission of In\ufb02uenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg. Infect. Dis. 2019, 25, 2108\u20132111. [CrossRef] Takashita, E.; Kawakami, C.; Ogawa, R.; Morita, H.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. In\ufb02uenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Eurosurveillance 2019, 24, 1900170. [CrossRef] Govorkova, E.A.; Takashita, E.; Daniels, R.S.; Fujisaki, S.; Presser, L.D.; Patel, M.C.; Huang, W.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global update on the susceptibilities of human in\ufb02uenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antivir. Res. 2022, 200, 105281. [CrossRef] 10. Matsuzaki, Y.; Sugawara, K.; Furuse, Y.; Shimotai, Y.; Hongo, S.; Oshitani, H.; Mizuta, K.; Nishimura, H. Genetic Lineage and Reassortment of In\ufb02uenza C Viruses Circulating between 1947 and 2014. J. Virol. 2016, 90, 8251\u20138265. [CrossRef] 11. Huang, C.; Yu, J.; Hause, B.M.; Park, J.Y.; Sreenivasan, C.; Uprety, T.; Sheng, Z.; Wang, D.; Li, F. Emergence of new phylogenetic lineage of In\ufb02uenza D virus with broad antigenicity in California, United States. Emerg. Microbes Infect. 2021, 10, 739\u2013742. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 14. Mishin, V.P.; Patel, M.C.; Chesnokov, A.; De La Cruz, J.; Nguyen, H.T.; Lollis, L.; Hodges, E.; Jang, Y.; Barnes, J.; Uyeki, T.; et al. Susceptibility of In\ufb02uenza A, B, C, and D Viruses to Baloxavir. Emerg. Infect. Dis. 2019, 25, 1969\u20131972. [CrossRef] 15. Takada, K.; Kawakami, C.; Fan, S.; Chiba, S.; Zhong, G.; Gu, C.; Shimizu, K.; Takasaki, S.; Sakai-Tagawa, Y.; Lopes, T.J.S.; et al. A humanized MDCK cell line for the ef\ufb01cient isolation and propagation of human in\ufb02uenza viruses. Nat. Microbiol. 2019, 4, 1268\u20131273. [CrossRef] 16. Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of In\ufb02uenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front. Microbiol. 2018, 9, 3026. [CrossRef] 17. Tilmanis, D.; van Baalen, C.; Oh, D.Y.; Rossignol, J.-F.; Hurt, A.C. The susceptibility of circulating human in\ufb02uenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antivir. Res. 2017, 147, 142\u2013148. [CrossRef] 18. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Chiba, S.; Halfmann, P.; Nagai, H.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against COVID-19 Omicron Variant. N. Engl. J. Med. 2022, 386, 995\u2013998. [CrossRef] 8 of 10 Viruses 2023, 15, 244 19. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Halfmann, P.; Watanabe, S.; Maeda, K.; et al. Ef\ufb01cacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022, 386, 1475\u20131477. [CrossRef] 20. Takashita, E.; Yamayoshi, S.; Fukushi, S.; Suzuki, T.; Maeda, K.; Sakai-Tagawa, Y.; Ito, M.; Uraki, R.; Halfmann, P.; Watanabe, S.; et al. Ef\ufb01cacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N. Engl. J. Med. 2022, 387, 1236\u20131238. [CrossRef] 21. Takashita, E.; Yamayoshi, S.; Simon, V.; van Bakel, H.; Sordillo, E.M.; Pekosz, A.; Fukushi, S.; Suzuki, T.; Maeda, K.; Halfmann, P.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022, 387, 468\u2013470. [CrossRef] 22. Takashita, E.; Yamayoshi, S.; Halfmann, P.; Wilson, N.; Ries, H.; Richardson, A.; Bobholz, M.; Vuyk, W.; Maddox, R.; Baker, D.A.; et al."}, {"question": " What is the title of reference 9 in the text?", "answer": " Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020.", "ref_chunk": "Health, Labour and Welfare, Japan, grant number 21HA2003 and by JSPS KAKENHI, grant number JP18K10036. 7 of 10 Viruses 2023, 15, 244 Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Acknowledgments: We thank Susan Watson for scienti\ufb01c editing. Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest. References 1. 2. 3. 4. 5. 6. 7. 8. 9. Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 2017, 93, 449\u2013463. [CrossRef] Tisdale, M. In\ufb02uenza M2 Ion-Channel and Neuraminidase Inhibitors. In Antimicrobial Drug Resistance; Mayers, D.L., Ed.; Humana Press: Totowa, NJ, USA, 2009; Chapter 31; pp. 421\u2013447. Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of in\ufb02uenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633. [CrossRef] Takashita, E. In\ufb02uenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harb. Perspect. Med. 2020, 11, a038687. [CrossRef] Bright, R.A.; Medina, M.-J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of adamantane resistance among in\ufb02uenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005, 366, 1175\u20131181. [CrossRef] Imai, M.; Yamashita, M.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Kiso, M.; Murakami, J.; Yasuhara, A.; Takada, K.; Ito, M.; Nakajima, N.; et al. In\ufb02uenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are \ufb01t and transmit through respiratory droplets. Nat. Microbiol. 2019, 5, 27\u201333. [CrossRef] Takashita, E.; Ichikawa, M.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Human-to-Human Transmission of In\ufb02uenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg. Infect. Dis. 2019, 25, 2108\u20132111. [CrossRef] Takashita, E.; Kawakami, C.; Ogawa, R.; Morita, H.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. In\ufb02uenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Eurosurveillance 2019, 24, 1900170. [CrossRef] Govorkova, E.A.; Takashita, E.; Daniels, R.S.; Fujisaki, S.; Presser, L.D.; Patel, M.C.; Huang, W.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global update on the susceptibilities of human in\ufb02uenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antivir. Res. 2022, 200, 105281. [CrossRef] 10. Matsuzaki, Y.; Sugawara, K.; Furuse, Y.; Shimotai, Y.; Hongo, S.; Oshitani, H.; Mizuta, K.; Nishimura, H. Genetic Lineage and Reassortment of In\ufb02uenza C Viruses Circulating between 1947 and 2014. J. Virol. 2016, 90, 8251\u20138265. [CrossRef] 11. Huang, C.; Yu, J.; Hause, B.M.; Park, J.Y.; Sreenivasan, C.; Uprety, T.; Sheng, Z.; Wang, D.; Li, F. Emergence of new phylogenetic lineage of In\ufb02uenza D virus with broad antigenicity in California, United States. Emerg. Microbes Infect. 2021, 10, 739\u2013742. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 14. Mishin, V.P.; Patel, M.C.; Chesnokov, A.; De La Cruz, J.; Nguyen, H.T.; Lollis, L.; Hodges, E.; Jang, Y.; Barnes, J.; Uyeki, T.; et al. Susceptibility of In\ufb02uenza A, B, C, and D Viruses to Baloxavir. Emerg. Infect. Dis. 2019, 25, 1969\u20131972. [CrossRef] 15. Takada, K.; Kawakami, C.; Fan, S.; Chiba, S.; Zhong, G.; Gu, C.; Shimizu, K.; Takasaki, S.; Sakai-Tagawa, Y.; Lopes, T.J.S.; et al. A humanized MDCK cell line for the ef\ufb01cient isolation and propagation of human in\ufb02uenza viruses. Nat. Microbiol. 2019, 4, 1268\u20131273. [CrossRef] 16. Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of In\ufb02uenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front. Microbiol. 2018, 9, 3026. [CrossRef] 17. Tilmanis, D.; van Baalen, C.; Oh, D.Y.; Rossignol, J.-F.; Hurt, A.C. The susceptibility of circulating human in\ufb02uenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antivir. Res. 2017, 147, 142\u2013148. [CrossRef] 18. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Chiba, S.; Halfmann, P.; Nagai, H.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against COVID-19 Omicron Variant. N. Engl. J. Med. 2022, 386, 995\u2013998. [CrossRef] 8 of 10 Viruses 2023, 15, 244 19. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Halfmann, P.; Watanabe, S.; Maeda, K.; et al. Ef\ufb01cacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022, 386, 1475\u20131477. [CrossRef] 20. Takashita, E.; Yamayoshi, S.; Fukushi, S.; Suzuki, T.; Maeda, K.; Sakai-Tagawa, Y.; Ito, M.; Uraki, R.; Halfmann, P.; Watanabe, S.; et al. Ef\ufb01cacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N. Engl. J. Med. 2022, 387, 1236\u20131238. [CrossRef] 21. Takashita, E.; Yamayoshi, S.; Simon, V.; van Bakel, H.; Sordillo, E.M.; Pekosz, A.; Fukushi, S.; Suzuki, T.; Maeda, K.; Halfmann, P.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022, 387, 468\u2013470. [CrossRef] 22. Takashita, E.; Yamayoshi, S.; Halfmann, P.; Wilson, N.; Ries, H.; Richardson, A.; Bobholz, M.; Vuyk, W.; Maddox, R.; Baker, D.A.; et al."}, {"question": " Who characterized influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil?", "answer": " Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.", "ref_chunk": "Health, Labour and Welfare, Japan, grant number 21HA2003 and by JSPS KAKENHI, grant number JP18K10036. 7 of 10 Viruses 2023, 15, 244 Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Acknowledgments: We thank Susan Watson for scienti\ufb01c editing. Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest. References 1. 2. 3. 4. 5. 6. 7. 8. 9. Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 2017, 93, 449\u2013463. [CrossRef] Tisdale, M. In\ufb02uenza M2 Ion-Channel and Neuraminidase Inhibitors. In Antimicrobial Drug Resistance; Mayers, D.L., Ed.; Humana Press: Totowa, NJ, USA, 2009; Chapter 31; pp. 421\u2013447. Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of in\ufb02uenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633. [CrossRef] Takashita, E. In\ufb02uenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harb. Perspect. Med. 2020, 11, a038687. [CrossRef] Bright, R.A.; Medina, M.-J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of adamantane resistance among in\ufb02uenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005, 366, 1175\u20131181. [CrossRef] Imai, M.; Yamashita, M.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Kiso, M.; Murakami, J.; Yasuhara, A.; Takada, K.; Ito, M.; Nakajima, N.; et al. In\ufb02uenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are \ufb01t and transmit through respiratory droplets. Nat. Microbiol. 2019, 5, 27\u201333. [CrossRef] Takashita, E.; Ichikawa, M.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Human-to-Human Transmission of In\ufb02uenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg. Infect. Dis. 2019, 25, 2108\u20132111. [CrossRef] Takashita, E.; Kawakami, C.; Ogawa, R.; Morita, H.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. In\ufb02uenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Eurosurveillance 2019, 24, 1900170. [CrossRef] Govorkova, E.A.; Takashita, E.; Daniels, R.S.; Fujisaki, S.; Presser, L.D.; Patel, M.C.; Huang, W.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global update on the susceptibilities of human in\ufb02uenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antivir. Res. 2022, 200, 105281. [CrossRef] 10. Matsuzaki, Y.; Sugawara, K.; Furuse, Y.; Shimotai, Y.; Hongo, S.; Oshitani, H.; Mizuta, K.; Nishimura, H. Genetic Lineage and Reassortment of In\ufb02uenza C Viruses Circulating between 1947 and 2014. J. Virol. 2016, 90, 8251\u20138265. [CrossRef] 11. Huang, C.; Yu, J.; Hause, B.M.; Park, J.Y.; Sreenivasan, C.; Uprety, T.; Sheng, Z.; Wang, D.; Li, F. Emergence of new phylogenetic lineage of In\ufb02uenza D virus with broad antigenicity in California, United States. Emerg. Microbes Infect. 2021, 10, 739\u2013742. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 14. Mishin, V.P.; Patel, M.C.; Chesnokov, A.; De La Cruz, J.; Nguyen, H.T.; Lollis, L.; Hodges, E.; Jang, Y.; Barnes, J.; Uyeki, T.; et al. Susceptibility of In\ufb02uenza A, B, C, and D Viruses to Baloxavir. Emerg. Infect. Dis. 2019, 25, 1969\u20131972. [CrossRef] 15. Takada, K.; Kawakami, C.; Fan, S.; Chiba, S.; Zhong, G.; Gu, C.; Shimizu, K.; Takasaki, S.; Sakai-Tagawa, Y.; Lopes, T.J.S.; et al. A humanized MDCK cell line for the ef\ufb01cient isolation and propagation of human in\ufb02uenza viruses. Nat. Microbiol. 2019, 4, 1268\u20131273. [CrossRef] 16. Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of In\ufb02uenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front. Microbiol. 2018, 9, 3026. [CrossRef] 17. Tilmanis, D.; van Baalen, C.; Oh, D.Y.; Rossignol, J.-F.; Hurt, A.C. The susceptibility of circulating human in\ufb02uenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antivir. Res. 2017, 147, 142\u2013148. [CrossRef] 18. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Chiba, S.; Halfmann, P.; Nagai, H.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against COVID-19 Omicron Variant. N. Engl. J. Med. 2022, 386, 995\u2013998. [CrossRef] 8 of 10 Viruses 2023, 15, 244 19. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Halfmann, P.; Watanabe, S.; Maeda, K.; et al. Ef\ufb01cacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022, 386, 1475\u20131477. [CrossRef] 20. Takashita, E.; Yamayoshi, S.; Fukushi, S.; Suzuki, T.; Maeda, K.; Sakai-Tagawa, Y.; Ito, M.; Uraki, R.; Halfmann, P.; Watanabe, S.; et al. Ef\ufb01cacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N. Engl. J. Med. 2022, 387, 1236\u20131238. [CrossRef] 21. Takashita, E.; Yamayoshi, S.; Simon, V.; van Bakel, H.; Sordillo, E.M.; Pekosz, A.; Fukushi, S.; Suzuki, T.; Maeda, K.; Halfmann, P.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022, 387, 468\u2013470. [CrossRef] 22. Takashita, E.; Yamayoshi, S.; Halfmann, P.; Wilson, N.; Ries, H.; Richardson, A.; Bobholz, M.; Vuyk, W.; Maddox, R.; Baker, D.A.; et al."}, {"question": " What is the title of reference 10 in the text?", "answer": " Genetic Lineage and Reassortment of Influenza C Viruses Circulating between 1947 and 2014.", "ref_chunk": "Health, Labour and Welfare, Japan, grant number 21HA2003 and by JSPS KAKENHI, grant number JP18K10036. 7 of 10 Viruses 2023, 15, 244 Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Acknowledgments: We thank Susan Watson for scienti\ufb01c editing. Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest. References 1. 2. 3. 4. 5. 6. 7. 8. 9. Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 2017, 93, 449\u2013463. [CrossRef] Tisdale, M. In\ufb02uenza M2 Ion-Channel and Neuraminidase Inhibitors. In Antimicrobial Drug Resistance; Mayers, D.L., Ed.; Humana Press: Totowa, NJ, USA, 2009; Chapter 31; pp. 421\u2013447. Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of in\ufb02uenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633. [CrossRef] Takashita, E. In\ufb02uenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harb. Perspect. Med. 2020, 11, a038687. [CrossRef] Bright, R.A.; Medina, M.-J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of adamantane resistance among in\ufb02uenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005, 366, 1175\u20131181. [CrossRef] Imai, M.; Yamashita, M.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Kiso, M.; Murakami, J.; Yasuhara, A.; Takada, K.; Ito, M.; Nakajima, N.; et al. In\ufb02uenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are \ufb01t and transmit through respiratory droplets. Nat. Microbiol. 2019, 5, 27\u201333. [CrossRef] Takashita, E.; Ichikawa, M.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Human-to-Human Transmission of In\ufb02uenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg. Infect. Dis. 2019, 25, 2108\u20132111. [CrossRef] Takashita, E.; Kawakami, C.; Ogawa, R.; Morita, H.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. In\ufb02uenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Eurosurveillance 2019, 24, 1900170. [CrossRef] Govorkova, E.A.; Takashita, E.; Daniels, R.S.; Fujisaki, S.; Presser, L.D.; Patel, M.C.; Huang, W.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global update on the susceptibilities of human in\ufb02uenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antivir. Res. 2022, 200, 105281. [CrossRef] 10. Matsuzaki, Y.; Sugawara, K.; Furuse, Y.; Shimotai, Y.; Hongo, S.; Oshitani, H.; Mizuta, K.; Nishimura, H. Genetic Lineage and Reassortment of In\ufb02uenza C Viruses Circulating between 1947 and 2014. J. Virol. 2016, 90, 8251\u20138265. [CrossRef] 11. Huang, C.; Yu, J.; Hause, B.M.; Park, J.Y.; Sreenivasan, C.; Uprety, T.; Sheng, Z.; Wang, D.; Li, F. Emergence of new phylogenetic lineage of In\ufb02uenza D virus with broad antigenicity in California, United States. Emerg. Microbes Infect. 2021, 10, 739\u2013742. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 14. Mishin, V.P.; Patel, M.C.; Chesnokov, A.; De La Cruz, J.; Nguyen, H.T.; Lollis, L.; Hodges, E.; Jang, Y.; Barnes, J.; Uyeki, T.; et al. Susceptibility of In\ufb02uenza A, B, C, and D Viruses to Baloxavir. Emerg. Infect. Dis. 2019, 25, 1969\u20131972. [CrossRef] 15. Takada, K.; Kawakami, C.; Fan, S.; Chiba, S.; Zhong, G.; Gu, C.; Shimizu, K.; Takasaki, S.; Sakai-Tagawa, Y.; Lopes, T.J.S.; et al. A humanized MDCK cell line for the ef\ufb01cient isolation and propagation of human in\ufb02uenza viruses. Nat. Microbiol. 2019, 4, 1268\u20131273. [CrossRef] 16. Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of In\ufb02uenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front. Microbiol. 2018, 9, 3026. [CrossRef] 17. Tilmanis, D.; van Baalen, C.; Oh, D.Y.; Rossignol, J.-F.; Hurt, A.C. The susceptibility of circulating human in\ufb02uenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antivir. Res. 2017, 147, 142\u2013148. [CrossRef] 18. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Chiba, S.; Halfmann, P.; Nagai, H.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against COVID-19 Omicron Variant. N. Engl. J. Med. 2022, 386, 995\u2013998. [CrossRef] 8 of 10 Viruses 2023, 15, 244 19. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Halfmann, P.; Watanabe, S.; Maeda, K.; et al. Ef\ufb01cacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022, 386, 1475\u20131477. [CrossRef] 20. Takashita, E.; Yamayoshi, S.; Fukushi, S.; Suzuki, T.; Maeda, K.; Sakai-Tagawa, Y.; Ito, M.; Uraki, R.; Halfmann, P.; Watanabe, S.; et al. Ef\ufb01cacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N. Engl. J. Med. 2022, 387, 1236\u20131238. [CrossRef] 21. Takashita, E.; Yamayoshi, S.; Simon, V.; van Bakel, H.; Sordillo, E.M.; Pekosz, A.; Fukushi, S.; Suzuki, T.; Maeda, K.; Halfmann, P.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022, 387, 468\u2013470. [CrossRef] 22. Takashita, E.; Yamayoshi, S.; Halfmann, P.; Wilson, N.; Ries, H.; Richardson, A.; Bobholz, M.; Vuyk, W.; Maddox, R.; Baker, D.A.; et al."}, {"question": " Who conducted the study on the susceptibility of circulating human influenza viruses to tizoxanide?", "answer": " Tilmanis, D.; van Baalen, C.; Oh, D.Y.; Rossignol, J.-F.; Hurt, A.C.", "ref_chunk": "Health, Labour and Welfare, Japan, grant number 21HA2003 and by JSPS KAKENHI, grant number JP18K10036. 7 of 10 Viruses 2023, 15, 244 Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Acknowledgments: We thank Susan Watson for scienti\ufb01c editing. Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest. References 1. 2. 3. 4. 5. 6. 7. 8. 9. Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 2017, 93, 449\u2013463. [CrossRef] Tisdale, M. In\ufb02uenza M2 Ion-Channel and Neuraminidase Inhibitors. In Antimicrobial Drug Resistance; Mayers, D.L., Ed.; Humana Press: Totowa, NJ, USA, 2009; Chapter 31; pp. 421\u2013447. Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of in\ufb02uenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633. [CrossRef] Takashita, E. In\ufb02uenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harb. Perspect. Med. 2020, 11, a038687. [CrossRef] Bright, R.A.; Medina, M.-J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of adamantane resistance among in\ufb02uenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005, 366, 1175\u20131181. [CrossRef] Imai, M.; Yamashita, M.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Kiso, M.; Murakami, J.; Yasuhara, A.; Takada, K.; Ito, M.; Nakajima, N.; et al. In\ufb02uenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are \ufb01t and transmit through respiratory droplets. Nat. Microbiol. 2019, 5, 27\u201333. [CrossRef] Takashita, E.; Ichikawa, M.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Human-to-Human Transmission of In\ufb02uenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg. Infect. Dis. 2019, 25, 2108\u20132111. [CrossRef] Takashita, E.; Kawakami, C.; Ogawa, R.; Morita, H.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. In\ufb02uenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Eurosurveillance 2019, 24, 1900170. [CrossRef] Govorkova, E.A.; Takashita, E.; Daniels, R.S.; Fujisaki, S.; Presser, L.D.; Patel, M.C.; Huang, W.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global update on the susceptibilities of human in\ufb02uenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antivir. Res. 2022, 200, 105281. [CrossRef] 10. Matsuzaki, Y.; Sugawara, K.; Furuse, Y.; Shimotai, Y.; Hongo, S.; Oshitani, H.; Mizuta, K.; Nishimura, H. Genetic Lineage and Reassortment of In\ufb02uenza C Viruses Circulating between 1947 and 2014. J. Virol. 2016, 90, 8251\u20138265. [CrossRef] 11. Huang, C.; Yu, J.; Hause, B.M.; Park, J.Y.; Sreenivasan, C.; Uprety, T.; Sheng, Z.; Wang, D.; Li, F. Emergence of new phylogenetic lineage of In\ufb02uenza D virus with broad antigenicity in California, United States. Emerg. Microbes Infect. 2021, 10, 739\u2013742. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 14. Mishin, V.P.; Patel, M.C.; Chesnokov, A.; De La Cruz, J.; Nguyen, H.T.; Lollis, L.; Hodges, E.; Jang, Y.; Barnes, J.; Uyeki, T.; et al. Susceptibility of In\ufb02uenza A, B, C, and D Viruses to Baloxavir. Emerg. Infect. Dis. 2019, 25, 1969\u20131972. [CrossRef] 15. Takada, K.; Kawakami, C.; Fan, S.; Chiba, S.; Zhong, G.; Gu, C.; Shimizu, K.; Takasaki, S.; Sakai-Tagawa, Y.; Lopes, T.J.S.; et al. A humanized MDCK cell line for the ef\ufb01cient isolation and propagation of human in\ufb02uenza viruses. Nat. Microbiol. 2019, 4, 1268\u20131273. [CrossRef] 16. Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of In\ufb02uenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front. Microbiol. 2018, 9, 3026. [CrossRef] 17. Tilmanis, D.; van Baalen, C.; Oh, D.Y.; Rossignol, J.-F.; Hurt, A.C. The susceptibility of circulating human in\ufb02uenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antivir. Res. 2017, 147, 142\u2013148. [CrossRef] 18. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Chiba, S.; Halfmann, P.; Nagai, H.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against COVID-19 Omicron Variant. N. Engl. J. Med. 2022, 386, 995\u2013998. [CrossRef] 8 of 10 Viruses 2023, 15, 244 19. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Halfmann, P.; Watanabe, S.; Maeda, K.; et al. Ef\ufb01cacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022, 386, 1475\u20131477. [CrossRef] 20. Takashita, E.; Yamayoshi, S.; Fukushi, S.; Suzuki, T.; Maeda, K.; Sakai-Tagawa, Y.; Ito, M.; Uraki, R.; Halfmann, P.; Watanabe, S.; et al. Ef\ufb01cacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N. Engl. J. Med. 2022, 387, 1236\u20131238. [CrossRef] 21. Takashita, E.; Yamayoshi, S.; Simon, V.; van Bakel, H.; Sordillo, E.M.; Pekosz, A.; Fukushi, S.; Suzuki, T.; Maeda, K.; Halfmann, P.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022, 387, 468\u2013470. [CrossRef] 22. Takashita, E.; Yamayoshi, S.; Halfmann, P.; Wilson, N.; Ries, H.; Richardson, A.; Bobholz, M.; Vuyk, W.; Maddox, R.; Baker, D.A.; et al."}, {"question": " What is the title of reference 16 in the text?", "answer": " Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.", "ref_chunk": "Health, Labour and Welfare, Japan, grant number 21HA2003 and by JSPS KAKENHI, grant number JP18K10036. 7 of 10 Viruses 2023, 15, 244 Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Acknowledgments: We thank Susan Watson for scienti\ufb01c editing. Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest. References 1. 2. 3. 4. 5. 6. 7. 8. 9. Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 2017, 93, 449\u2013463. [CrossRef] Tisdale, M. In\ufb02uenza M2 Ion-Channel and Neuraminidase Inhibitors. In Antimicrobial Drug Resistance; Mayers, D.L., Ed.; Humana Press: Totowa, NJ, USA, 2009; Chapter 31; pp. 421\u2013447. Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of in\ufb02uenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633. [CrossRef] Takashita, E. In\ufb02uenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harb. Perspect. Med. 2020, 11, a038687. [CrossRef] Bright, R.A.; Medina, M.-J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of adamantane resistance among in\ufb02uenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005, 366, 1175\u20131181. [CrossRef] Imai, M.; Yamashita, M.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Kiso, M.; Murakami, J.; Yasuhara, A.; Takada, K.; Ito, M.; Nakajima, N.; et al. In\ufb02uenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are \ufb01t and transmit through respiratory droplets. Nat. Microbiol. 2019, 5, 27\u201333. [CrossRef] Takashita, E.; Ichikawa, M.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Human-to-Human Transmission of In\ufb02uenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg. Infect. Dis. 2019, 25, 2108\u20132111. [CrossRef] Takashita, E.; Kawakami, C.; Ogawa, R.; Morita, H.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. In\ufb02uenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Eurosurveillance 2019, 24, 1900170. [CrossRef] Govorkova, E.A.; Takashita, E.; Daniels, R.S.; Fujisaki, S.; Presser, L.D.; Patel, M.C.; Huang, W.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global update on the susceptibilities of human in\ufb02uenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antivir. Res. 2022, 200, 105281. [CrossRef] 10. Matsuzaki, Y.; Sugawara, K.; Furuse, Y.; Shimotai, Y.; Hongo, S.; Oshitani, H.; Mizuta, K.; Nishimura, H. Genetic Lineage and Reassortment of In\ufb02uenza C Viruses Circulating between 1947 and 2014. J. Virol. 2016, 90, 8251\u20138265. [CrossRef] 11. Huang, C.; Yu, J.; Hause, B.M.; Park, J.Y.; Sreenivasan, C.; Uprety, T.; Sheng, Z.; Wang, D.; Li, F. Emergence of new phylogenetic lineage of In\ufb02uenza D virus with broad antigenicity in California, United States. Emerg. Microbes Infect. 2021, 10, 739\u2013742. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 14. Mishin, V.P.; Patel, M.C.; Chesnokov, A.; De La Cruz, J.; Nguyen, H.T.; Lollis, L.; Hodges, E.; Jang, Y.; Barnes, J.; Uyeki, T.; et al. Susceptibility of In\ufb02uenza A, B, C, and D Viruses to Baloxavir. Emerg. Infect. Dis. 2019, 25, 1969\u20131972. [CrossRef] 15. Takada, K.; Kawakami, C.; Fan, S.; Chiba, S.; Zhong, G.; Gu, C.; Shimizu, K.; Takasaki, S.; Sakai-Tagawa, Y.; Lopes, T.J.S.; et al. A humanized MDCK cell line for the ef\ufb01cient isolation and propagation of human in\ufb02uenza viruses. Nat. Microbiol. 2019, 4, 1268\u20131273. [CrossRef] 16. Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of In\ufb02uenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front. Microbiol. 2018, 9, 3026. [CrossRef] 17. Tilmanis, D.; van Baalen, C.; Oh, D.Y.; Rossignol, J.-F.; Hurt, A.C. The susceptibility of circulating human in\ufb02uenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antivir. Res. 2017, 147, 142\u2013148. [CrossRef] 18. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Chiba, S.; Halfmann, P.; Nagai, H.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against COVID-19 Omicron Variant. N. Engl. J. Med. 2022, 386, 995\u2013998. [CrossRef] 8 of 10 Viruses 2023, 15, 244 19. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Halfmann, P.; Watanabe, S.; Maeda, K.; et al. Ef\ufb01cacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022, 386, 1475\u20131477. [CrossRef] 20. Takashita, E.; Yamayoshi, S.; Fukushi, S.; Suzuki, T.; Maeda, K.; Sakai-Tagawa, Y.; Ito, M.; Uraki, R.; Halfmann, P.; Watanabe, S.; et al. Ef\ufb01cacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N. Engl. J. Med. 2022, 387, 1236\u20131238. [CrossRef] 21. Takashita, E.; Yamayoshi, S.; Simon, V.; van Bakel, H.; Sordillo, E.M.; Pekosz, A.; Fukushi, S.; Suzuki, T.; Maeda, K.; Halfmann, P.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022, 387, 468\u2013470. [CrossRef] 22. Takashita, E.; Yamayoshi, S.; Halfmann, P.; Wilson, N.; Ries, H.; Richardson, A.; Bobholz, M.; Vuyk, W.; Maddox, R.; Baker, D.A.; et al."}], "doc_text": "Health, Labour and Welfare, Japan, grant number 21HA2003 and by JSPS KAKENHI, grant number JP18K10036. 7 of 10 Viruses 2023, 15, 244 Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Acknowledgments: We thank Susan Watson for scienti\ufb01c editing. Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest. References 1. 2. 3. 4. 5. 6. 7. 8. 9. Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 2017, 93, 449\u2013463. [CrossRef] Tisdale, M. In\ufb02uenza M2 Ion-Channel and Neuraminidase Inhibitors. In Antimicrobial Drug Resistance; Mayers, D.L., Ed.; Humana Press: Totowa, NJ, USA, 2009; Chapter 31; pp. 421\u2013447. Omoto, S.; Speranzini, V.; Hashimoto, T.; Noshi, T.; Yamaguchi, H.; Kawai, M.; Kawaguchi, K.; Uehara, T.; Shishido, T.; Naito, A.; et al. Characterization of in\ufb02uenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 2018, 8, 9633. [CrossRef] Takashita, E. In\ufb02uenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harb. Perspect. Med. 2020, 11, a038687. [CrossRef] Bright, R.A.; Medina, M.-J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of adamantane resistance among in\ufb02uenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005, 366, 1175\u20131181. [CrossRef] Imai, M.; Yamashita, M.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Kiso, M.; Murakami, J.; Yasuhara, A.; Takada, K.; Ito, M.; Nakajima, N.; et al. In\ufb02uenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are \ufb01t and transmit through respiratory droplets. Nat. Microbiol. 2019, 5, 27\u201333. [CrossRef] Takashita, E.; Ichikawa, M.; Morita, H.; Ogawa, R.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. Human-to-Human Transmission of In\ufb02uenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg. Infect. Dis. 2019, 25, 2108\u20132111. [CrossRef] Takashita, E.; Kawakami, C.; Ogawa, R.; Morita, H.; Fujisaki, S.; Shirakura, M.; Miura, H.; Nakamura, K.; Kishida, N.; Kuwahara, T.; et al. In\ufb02uenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Eurosurveillance 2019, 24, 1900170. [CrossRef] Govorkova, E.A.; Takashita, E.; Daniels, R.S.; Fujisaki, S.; Presser, L.D.; Patel, M.C.; Huang, W.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global update on the susceptibilities of human in\ufb02uenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antivir. Res. 2022, 200, 105281. [CrossRef] 10. Matsuzaki, Y.; Sugawara, K.; Furuse, Y.; Shimotai, Y.; Hongo, S.; Oshitani, H.; Mizuta, K.; Nishimura, H. Genetic Lineage and Reassortment of In\ufb02uenza C Viruses Circulating between 1947 and 2014. J. Virol. 2016, 90, 8251\u20138265. [CrossRef] 11. Huang, C.; Yu, J.; Hause, B.M.; Park, J.Y.; Sreenivasan, C.; Uprety, T.; Sheng, Z.; Wang, D.; Li, F. Emergence of new phylogenetic lineage of In\ufb02uenza D virus with broad antigenicity in California, United States. Emerg. Microbes Infect. 2021, 10, 739\u2013742. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 12. Peng, Q.; Liu, Y.; Peng, R.; Wang, M.; Yang, W.; Song, H.; Chen, Y.; Liu, S.; Han, M.; Zhang, X.; et al. Structural insight into RNA synthesis by in\ufb02uenza D polymerase. Nat. Microbiol. 2019, 4, 1750\u20131759. [CrossRef] Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; et al. In Vitro and In Vivo Activities of Anti-In\ufb02uenza Virus Compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977\u2013981. [CrossRef] 14. Mishin, V.P.; Patel, M.C.; Chesnokov, A.; De La Cruz, J.; Nguyen, H.T.; Lollis, L.; Hodges, E.; Jang, Y.; Barnes, J.; Uyeki, T.; et al. Susceptibility of In\ufb02uenza A, B, C, and D Viruses to Baloxavir. Emerg. Infect. Dis. 2019, 25, 1969\u20131972. [CrossRef] 15. Takada, K.; Kawakami, C.; Fan, S.; Chiba, S.; Zhong, G.; Gu, C.; Shimizu, K.; Takasaki, S.; Sakai-Tagawa, Y.; Lopes, T.J.S.; et al. A humanized MDCK cell line for the ef\ufb01cient isolation and propagation of human in\ufb02uenza viruses. Nat. Microbiol. 2019, 4, 1268\u20131273. [CrossRef] 16. Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of In\ufb02uenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front. Microbiol. 2018, 9, 3026. [CrossRef] 17. Tilmanis, D.; van Baalen, C.; Oh, D.Y.; Rossignol, J.-F.; Hurt, A.C. The susceptibility of circulating human in\ufb02uenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antivir. Res. 2017, 147, 142\u2013148. [CrossRef] 18. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Chiba, S.; Halfmann, P.; Nagai, H.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against COVID-19 Omicron Variant. N. Engl. J. Med. 2022, 386, 995\u2013998. [CrossRef] 8 of 10 Viruses 2023, 15, 244 19. Takashita, E.; Kinoshita, N.; Yamayoshi, S.; Sakai-Tagawa, Y.; Fujisaki, S.; Ito, M.; Iwatsuki-Horimoto, K.; Halfmann, P.; Watanabe, S.; Maeda, K.; et al. Ef\ufb01cacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022, 386, 1475\u20131477. [CrossRef] 20. Takashita, E.; Yamayoshi, S.; Fukushi, S.; Suzuki, T.; Maeda, K.; Sakai-Tagawa, Y.; Ito, M.; Uraki, R.; Halfmann, P.; Watanabe, S.; et al. Ef\ufb01cacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N. Engl. J. Med. 2022, 387, 1236\u20131238. [CrossRef] 21. Takashita, E.; Yamayoshi, S.; Simon, V.; van Bakel, H.; Sordillo, E.M.; Pekosz, A.; Fukushi, S.; Suzuki, T.; Maeda, K.; Halfmann, P.; et al. Ef\ufb01cacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022, 387, 468\u2013470. [CrossRef] 22. Takashita, E.; Yamayoshi, S.; Halfmann, P.; Wilson, N.; Ries, H.; Richardson, A.; Bobholz, M.; Vuyk, W.; Maddox, R.; Baker, D.A.; et al."}